Published in J Clin Invest on November 01, 1981
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest (2006) 4.50
The eicosanoids and their biochemical mechanisms of action. Biochem J (1989) 2.35
Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma. J Clin Invest (2003) 2.27
Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest (1982) 2.23
Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest (1983) 2.13
Arachidonate metabolism in vascular disorders. J Clin Invest (1983) 1.43
Factors that influence the outcome of primary pulmonary hypertension. Br Heart J (1986) 1.41
Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci U S A (2001) 1.38
Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. J Clin Invest (2001) 1.29
Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man. J Clin Invest (1983) 1.21
Contribution of prostaglandins to the systemic and renal vascular response to frusemide in normal man. Br J Clin Pharmacol (1984) 1.17
Estimated rate of thromboxane secretion into the circulation of normal humans. J Clin Invest (1986) 1.15
Effect of vasoactive peptides on prostacyclin synthesis in man. Br J Pharmacol (1986) 1.14
Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon. Br Med J (Clin Res Ed) (1986) 1.10
Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut (2001) 1.05
Prostaglandins, thromboxanes and leukotrienes in clinical medicine. West J Med (1985) 1.02
Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. Br J Clin Pharmacol (2011) 0.99
Antiplatelet drugs. Br J Pharmacol (2006) 0.98
COX-2, the dominant source of prostacyclin. Proc Natl Acad Sci U S A (2013) 0.96
Regulation of vascular prostaglandin synthesis by metabolites of arachidonic acid in perfused rabbit aorta. J Clin Invest (1983) 0.93
Redirection of prostaglandin endoperoxide metabolism at the platelet-vascular interface in man. J Clin Invest (1989) 0.91
Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis. J Clin Invest (1988) 0.89
Prostaglandins, the kidney, and hypertension. West J Med (1990) 0.84
Abnormalities in the biosynthesis of thromboxane A2 and prostacyclin in children with cyanotic congenital heart disease. Br Heart J (1993) 0.83
In vivo production of prostacyclin and thromboxane in patients with acute myocardial infarction. Br Heart J (1986) 0.83
Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism. Circ Res (2013) 0.81
Excretion of metabolites of prostacyclin and thromboxane by rats with nephrotoxic nephritis: effects of interleukin-1. Br J Pharmacol (1991) 0.80
Prostanoid synthesis by aortic rings in human blood: selective increase of prostacyclin mediated by a serum factor. Br J Pharmacol (1984) 0.79
Major urinary metabolites of 6-keto-prostaglandin F2α in mice. J Lipid Res (2013) 0.78
High-fat diet alters prostanoid balance and perfusion in ischemic myocardium of naproxen-treated swine. Surgery (2011) 0.78
Dipyridamole: pharmacokinetics and effects on aspects of platelet function in man. Br J Clin Pharmacol (1987) 0.77
Evidence that prostacyclin modulates the vascular actions of calcium in man. J Clin Invest (1986) 0.76
Urinary excretion of 6-keto prostaglandin F1 alpha in pre-eclampsia. Arch Gynecol Obstet (1988) 0.75
A new target for squamous cell skin cancer? Exp Dermatol (2015) 0.75
The effect of platelet inhibitory therapy on graft thromboresistance. Int J Exp Pathol (1993) 0.75
Comparison of the effects of selective inhibition of thromboxane synthase with those of inhibition of the cyclooxygenase enzyme in man. Trans Am Clin Climatol Assoc (1984) 0.75
Effects of mild exercise on serum lipoproteins and metabolites of arachidonic acid. Br Med J (Clin Res Ed) (1984) 0.75
COX-2 Inhibition by Use of Rofecoxib or High Dose Aspirin Enhances ADP-Induced Platelet Aggregation in Fresh Blood. Open Cardiovasc Med J (2010) 0.75
Prostaglandins: their disappearance from and release into the circulation. Nature (1967) 8.66
Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins (1977) 3.80
Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. Br Med Bull (1978) 2.51
Generation of prostacyclin by lungs in vivo and its release into the arterial circulation. Nature (1978) 2.10
Comparison of the vasodepressor effects of prostacyclin and 6-oxo-prostaglandin F1alpha with those of prostaglandin E2 in rats and rabbits. Br J Pharmacol (1978) 1.85
A double blind placebo controlled crossover study of prostacyclin in man. Life Sci (1979) 1.67
Prostacyclin is a circulating hormone. Nature (1978) 1.60
Measurement of 6-oxo-PGF1 alpha in human plasma using gas chromatography-mass spectrometry. Prostaglandins (1979) 1.48
Metabolism of prostacyclin and 6-keto-prostaglandin F1 alpha in man. J Biol Chem (1980) 1.21
In vivo method for quantitation for anti-platelet potency of drugs. Naunyn Schmiedebergs Arch Pharmacol (1978) 1.17
A sensitive radioimmunoassay for 6-keto-prostaglandin F1alpha: preliminary observations on circulating concentrations. Prostaglandins Med (1978) 1.13
Production of 6-oxo-PGF1 alpha by human lung in vivo. Lancet (1979) 1.11
Antibodies which antagonise the effects of prostacyclin. Nature (1978) 1.10
Is prostacyclin a physiologically important circulating anti-platelet agent? Nature (1980) 1.03
Quantitative determination of 6-Oxo-PGF1 alpha in biological fluids by gas chromatography mass spectrometry. Biomed Mass Spectrom (1980) 1.01
PGI2-specific antibodies administered in vivo suggest against a role for endogenous PGI2 as a circulating vasodepressor hormone in the normotensive and spontaneously hypertensive rat. Prostaglandins (1980) 0.99
Identification of the major metabolite of prostacyclin and 6-ketoprostaglandin F1 alpha in man. Biochim Biophys Acta (1980) 0.93
Plasma propranolol levels in adults with observations in four children. Clin Pharmacol Ther (1970) 9.54
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet (2013) 8.16
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med (2001) 5.96
Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A (1999) 4.16
Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med (1995) 3.91
Urinary prostaglandins. Identification and origin. J Clin Invest (1975) 3.07
Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J Immunol (1982) 2.69
The relative efficacy of guanethidine, methyldopa and pargyline as antihypertensive agents. N Engl J Med (1965) 2.64
Prostaglandins as mediators of hypercalcemia associated with certain types of cancer. N Engl J Med (1975) 2.63
Platelet activation in unstable coronary disease. N Engl J Med (1986) 2.60
Regulation of CLOCK and MOP4 by nuclear hormone receptors in the vasculature: a humoral mechanism to reset a peripheral clock. Cell (2001) 2.59
Effects of vitamin E on lipid peroxidation in healthy persons. JAMA (2001) 2.58
Effects of caffeine on plasma renin activity, catecholamines and blood pressure. N Engl J Med (1978) 2.50
Coronary arterial smooth muscle contraction by a substance released from platelets: evidence that it is thromboxane A2. Science (1976) 2.39
The antihypertensive effects of fish oil. A controlled study of polyunsaturated fatty acid supplements in essential hypertension. N Engl J Med (1989) 2.36
Clinical experience over 48 years with pheochromocytoma. Ann Surg (1999) 2.32
Guanethidine and related agents. 3. Antagonism by drugs which inhibit the norepinephrine pump in man. J Clin Invest (1970) 2.29
Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat Med (1999) 2.26
Platelet-active drugs : the relationships among dose, effectiveness, and side effects. Chest (2001) 2.25
Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest (2001) 2.19
Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest (1983) 2.13
Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther (1999) 2.10
Purification of an allene oxide synthase and identification of the enzyme as a cytochrome P-450. Science (1991) 2.06
Release of prostaglandin D2 into human airways during acute antigen challenge. N Engl J Med (1986) 2.03
Tolerance to the humoral and hemodynamic effects of caffeine in man. J Clin Invest (1981) 2.03
Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med (1984) 2.00
Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat Med (1998) 1.98
Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood (1987) 1.96
Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest (1997) 1.90
Comparative assessment of stimuli that release neuronal and adrenomedullary catecholamines in man. Circulation (1979) 1.88
Two distinct pathways of formation of 4-hydroxynonenal. Mechanisms of nonenzymatic transformation of the 9- and 13-hydroperoxides of linoleic acid to 4-hydroxyalkenals. J Biol Chem (2001) 1.87
Molecular cloning of an allene oxide synthase: a cytochrome P450 specialized for the metabolism of fatty acid hydroperoxides. Proc Natl Acad Sci U S A (1993) 1.87
Dopamine receptor subtypes: beyond the D1/D2 classification. Trends Pharmacol Sci (1990) 1.85
Ionophores stimulate prostaglandin and thromboxane biosynthesis. Proc Natl Acad Sci U S A (1977) 1.82
Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation (1999) 1.79
Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol (2000) 1.79
Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J Clin Invest (2000) 1.78
Molecular cloning and expression of the gene for a human D1 dopamine receptor. Nature (1990) 1.75
Pharmacologic and endocrine aspects of carcinoid syndrome. Adv Pharmacol (1967) 1.74
Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation (1991) 1.74
Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation (1996) 1.74
Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation (1983) 1.73
Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med (1984) 1.73
Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest (1998) 1.73
Angioplasty increases coronary sinus F2-isoprostane formation: evidence for in vivo oxidative stress during PTCA. J Am Coll Cardiol (2001) 1.71
Antagonism of the antihypertensive action of guanethidine sulfate by desipramine hydrochloride. JAMA (1967) 1.67
A double blind placebo controlled crossover study of prostacyclin in man. Life Sci (1979) 1.67
Increased production of prostaglandin D2 in patients with systemic mastocytosis. N Engl J Med (1980) 1.63
Suppression of plasma renin activity by indomethacin in man. Circ Res (1976) 1.62
Modulation of human neutrophil function by monohydroxy-eicosatetraenoic acids. Immunology (1980) 1.60
Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype. J Biol Chem (1993) 1.59
Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med (1991) 1.58
Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype. Br J Clin Pharmacol (1978) 1.57
Straight phase separation of prostaglandin methyl esters on lipophilic gels. Prostaglandins (1974) 1.56
Thromboxane A2 synthesis in pregnancy-induced hypertension. Lancet (1990) 1.56
Alcohol-induced generation of lipid peroxidation products in humans. J Clin Invest (1999) 1.55
Bartter's syndrome: a disorder characterized by high urinary prostaglandins and a dependence of hyperreninemia on prostaglandin synthesis. Am J Med (1976) 1.55
Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med (1994) 1.54
Platelet activation by superoxide anion and hydroxyl radicals intrinsically generated by platelets that had undergone anoxia and then reoxygenated. Circulation (1997) 1.54
Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol (1997) 1.53
Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J Biol Chem (1999) 1.53
Identification of a naturally occurring peroxidase-lipoxygenase fusion protein. Science (1997) 1.52
Two polymorphisms in the human lipoprotein lipase (LPL) gene. Nucleic Acids Res (1987) 1.51
Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation (1988) 1.49
Indices of lipid peroxidation in vivo: strengths and limitations. Free Radic Biol Med (2000) 1.48
Dipyridamole. N Engl J Med (1987) 1.48
Resolution of prostaglandin endoperoxide synthase and thromboxane synthase of human platelets. Proc Natl Acad Sci U S A (1977) 1.47
Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice. Circulation (2001) 1.46
Effects of celecoxib on major prostaglandins in asthma. Clin Exp Allergy (2010) 1.45
Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F(2)-isoprostanes in human urine. Proc Natl Acad Sci U S A (1999) 1.45
Clinical implications of prostaglandin and thromboxane A2 formation (1). N Engl J Med (1988) 1.45
Chlorpromazine reversal of the antihypertensive action of guanethidine. Lancet (1971) 1.43
IPF2alpha-I: an index of lipid peroxidation in humans. Proc Natl Acad Sci U S A (1998) 1.43
Hypertension and fibromuscular dysplasia of the renal arteries. Surgery (1969) 1.42
8-epi PGF2 alpha generation during coronary reperfusion. A potential quantitative marker of oxidant stress in vivo. Circulation (1997) 1.41
Cloning, molecular characterization, and chromosomal assignment of a gene encoding a second D1 dopamine receptor subtype: differential expression pattern in rat brain compared with the D1A receptor. Proc Natl Acad Sci U S A (1991) 1.40
Inhibition of monoamine oxidase in man by furazolidone. Clin Pharmacol Ther (1968) 1.40
(R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2. Nat Chem Biol (2011) 1.39
Prostaglandin thromboxane, and 12-hydroxy-5,8,10,14-eicosatetraenoic acid production by ionophore-stimulated rat serosal mast cells. Biochim Biophys Acta (1979) 1.39
Inhibition of eicosanoid biosynthesis by glucocorticoids in humans. Proc Natl Acad Sci U S A (1990) 1.38
Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci U S A (2001) 1.38
Confusion in reperfusion. Problems in the clinical development of antithrombotic drugs. Circulation (1997) 1.38
Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J Clin Invest (1997) 1.38
Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med (1978) 1.37
Ablation of cyclooxygenase-2 in forebrain neurons is neuroprotective and dampens brain inflammation after status epilepticus. J Neurosci (2011) 1.37
Oxygenation of biological membranes by the pure reticulocyte lipoxygenase. J Biol Chem (1990) 1.37
15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res (2001) 1.37
Biosynthesis of prostaglandin D2. 1. Formation of prostaglandin D2 by human platelets. Prostaglandins (1977) 1.36
Purification and catalytic activities of the two domains of the allene oxide synthase-lipoxygenase fusion protein of the coral Plexaura homomalla. J Biol Chem (1999) 1.36
In vivo indexes of platelet and vascular function during fish-oil administration in patients with atherosclerosis. N Engl J Med (1986) 1.36
Metabolism of thromboxane B2 in man. Identification of twenty urinary metabolites. J Biol Chem (1981) 1.35
11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci U S A (1986) 1.35
Quantification of the major urinary metabolite of 15-F2t-isoprostane (8-iso-PGF2alpha) by a stable isotope dilution mass spectrometric assay. Anal Biochem (1999) 1.34
Relation between plasma concentration of indomethacin and its effect on prostaglandin synthesis and platelet aggregation in man. Clin Pharmacol Ther (1978) 1.33